Chester County News and Community Website
PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) reported its financial results for 2025 and outlined progress across its pipeline of stem cell-derived therapies, including plans to submit a regulatory …
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its board of directors, strengthening governance and strategic oversight as the …
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has unveiled its first program targeting Type 1 diabetes, introducing an engineered cell therapy designed to restore natural insulin production without the …
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported third quarter 2025 results and announced a major expansion of its pipeline with a new induced pluripotent stem cell (iPSC)-derived beta …
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that Chief Scientific Officer Chad Cowan, Ph.D., will deliver a presentation at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October …
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that CEO Brent Pfeiffenberger, Pharm.D., will deliver a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The event …
Century Therapeutics to Present at Global Investment Conference Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has announced its participation in the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, set to take place from June …
Century Therapeutics to Present Preclinical Data at EULAR 2025 Congress Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs. Highlights include updates on the …
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has announced two critical presentations at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place …
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss …
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances Read More